TITLE:
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

CONDITION:
Prostate Cancer

INTERVENTION:
AMG 162

SUMMARY:

      This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing
      Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Male
Age: 18 Years to N/A
Criteria:

        Other criteria also apply
      
